This study investigates metastatic pancreatic cancer. It compares the effects of an investigational medication combined with other treatments to a different medication regimen.
The study evaluates the safety and effectiveness of the treatments to understand their impact on the condition.
- Who can participate: Adults with confirmed metastatic pancreatic cancer who have not received prior treatment for this stage, have a life expectancy of at least three months, and an ECOG performance status of 0 or 1 can participate.
- Study details: Participants will receive either the investigational medication with additional treatments or a comparison regimen, which includes a placebo.